Citations

Clear

6273 citation(s) found for "To, Andrew".

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Armstrong, Andrew J., Morris, M., Abida, Wassim , Aggarwal, Rahul R., Antonarakis, Emmanuel S., Attard, Gerhardt , Beltran, Himisha, Bryce, Alan H. , Carducci, Michael A. , Cheng, Heather H., Dahut, William L. , Emmett, Louise , Fizazi, Karim, Gafita, Andrei, George, Daniel J., Hermann, Ken, Hofman, Michael S., Hope, MD Thomas A., Hussain, Maha, Kelly, W. Kevin, Kuo, Phillip H. , Liu, Glenn X., Morgans, Alicia K., McKay, Rana R., Nanus, David, Nelson, P., Reichert, Zachery R. , Ryan, Charles J. , Sartor, A. Oliver, Schwartz, Lawrence H., Sharifi, Nima , Stadler, Walter M., Stein, M., Sternberg, Cora N., Szmulewitz, Russell Z., Tagawa, Scott T., Sokolova, Alexandra O., Wyatt, Alex, Yu, Evan Y., Halabi, S., Scher, Howard I., Group, for the PCWG4 Writing, Alumkal, Joshi J. , Aparicio, Ana, Barata, Pedro C., Drake, Charles G., Hamid, Anis , Heath, Elisabeth I. , Nauseef, Jones, Lage, Daniel E. , Mallak, Nadine , Patnaik, Akash, Prepelica, Kristofer, Rowe, Steven P., Slovin, Susan F. , Taplin, Mary‐Ellen , Zorko, Nicholas, Carducci, Michael A. , Halabi, Susan , Cheng, Heather H. , Antonarakis, Emmanuel S. , Morris, Michael J. , Armstrong, Andrew J. , Nauseef, Jones T. , Antonarakis, Emmanuel S. , Zorko, Nicholas A. , Armstrong, Andrew J , Morris, Michael J , Aggarwal, Rahul , Antonarakis, Emmanuel S , Beltran, Himisha , Bryce, Alan H , Cheng, Heather H , Chen, Delphine L , Chi, Kim N , Childs, Daniel S , Dahut, William , Emmett, Louise , Fizazi, Karim , Gafita, Andrei , George, Daniel J , Hermann, Ken , Hofman, Michael S , Hope, Thomas A , Hussain, Maha H A , Kelly, W Kevin , Kessler, Elizabeth , Lang, Joshua M , Liu, Glenn , Marshall, Catherine H , Morgans, Alicia K , McKay, Rana R , Nelson, Peter S , Paller, Channing J , Reichert, Zachery R , Sartor, A Oliver , Schöder, Heiko , Sharifi, Nima , Stadler, Walter M , Stein, Mark , Sternberg, Cora N , Szmulewitz, Russell Z , Tagawa, Scott T , Sokolova, Alexandra O , Wyatt, Alexander , Yamoah, Kosj , Yu, Evan Y , Halabi, Susan , Antonarakis, Emmanuel S , Zorko, Nicholas A , Nauseef, Jones T , N., Kim , Childs, Daniel S. , Fizazi, Karim , Gafita, Andrei , George, Daniel J. , Hofman, Michael S. , Lang, Joshua M. , Liu, Glenn , Marshall, Catherine H. , Morgans, Alicia K. , McKay, Rana R. , Paller, Channing J. , Sartor, Oliver , Schöder, Heiko , Schwartz, Lawrence H., Stadler, Walter M. , Tagawa, Scott T. , Scher, Howard I. , Aparicio, Ana, Barata, Pedro C. , Drake, Charles G. , Graff, Julie Nicole , Patnaik, Akash , Rathkopf, Dana E , Rettig, Matthew B.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1249-1265

10.1200/jco-25-02834 | PMID 41744290 Get It

PURPOSE The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer. Methods We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced prostate cancer. RESULTS PCWG4 redefines terminology around the disease state and previous therapies in a patient-centric context and terminology focused on androgen pathway modulation. We consider imaging, with a particular focus on positron emission tomography (PET)–defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, response and delay/prevent end points, intervals for reassessments including imaging, and patient-reported outcome determination. We provide recommendations in a biomarker-based context of use for the intended indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework. CONCLUSION PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator–naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.
Recommendations for the Deprescribing of Psychotropic Medications
Goldberg, Joseph F. , McIntyre, R. S., Freeman, Marlene P. , Mago, Rajnish, Citrome, Leslie, Rosenblat, Joshua D., Thase, Michael E., Tohen, Mauricio, Vieta, Eduard, Malhi, Gin S, Sajatovic, M., Shelton, Richard C. , Macaluso, Matthew , Berk, Michael, Perlis, Roy H., Ostacher, Michael J., Khan, Arifulla, Sanacora, Gerard , Kane, John M., D, Goodman, Nierenberg, Andrew A., Correll, Christoph U., Kupka, R. W., Kasper, Siegfried, Furukawa, Toshi A., Davis, Lori L., Aaronson, Scott T., Gitlin, Michael , Jha, Manish K., Cohen, Lawrence J. , Papakostas, George I. , Mitchell, Philip B., Gorwood, P., Gupta, Swapnil , Frye, Mark A., Young, A. H., Zohar, Joseph, Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H. , Shelton, Richard C. , Young, Allan H. , Ostacher, Michael J. , Jha, Manish K. , Young, Allan H , Jha, Manish K , Ostacher, Michael J , McIntyre, Roger S. , Swartz, Holly A. , Citrome, Leslie , Rosenblat, Joshua D. , Thase, Michael E. , Tohen, Mauricio , Vieta, Eduard , Malhi, Gin S. , Sajatovic, Martha, Berk, Michael , Perlis, Roy H , Iosifescu, Dan Vlad , Rubio, Jose M , Kane, John M. , Nierenberg, Andrew A. , Correll, Christoph Ulrich , Kupka, Ralph , Kasper, Siegfried , Furukawa, Toshi A , Aaronson, Scott T. , Mitchell, Philip B , Gorwood, Philip , Frye, Mark A. , Zohar, Joseph , Zarate, Carlos A.

Mayo Clinic

JAMA Network Open | February 25, 2026 | Volume: 9 | Issue: 2 | Pages: e260043

10.1001/jamanetworkopen.2026.0043 | PMID 41739481 Get It

Importance There is a need for greater recognition of clinical psychopharmacology endpoints, including instances where specific psychotropic medications may become unnecessary, redundant, contradictory, or otherwise inappropriate and therefore merit deprescribing. Objective To address circumstances warranting psychotropic medication deprescribing. Evidence Review The American Society of Clinical Psychopharmacology convened a panel of 45 international psychopharmacology experts who developed and completed a multiround Delphi survey and conducted a focused literature review between January and May of 2025, in order to identify areas of consensus or disagreement on key aspects of the deprescribing of psychotropic medications. These included collaborative risk-benefit assessments with patients; pharmacokinetic and pharmacodynamic factors; pharmacogenomics; distinguishing redundant or conflictual from complementary mechanisms of action; managing adverse effects; assuring medication adherence; drug tolerance or tachyphylaxis; medication misuse; and the psychological context and ramifications of deprescribing. Findings Consensus was achieved on 44 of 50 final Delphi statements (88%). Panelists unanimously agreed that components of a pharmacotherapy regimen should undergo periodic review to ensure that treatments target relevant symptoms and have favorable risk-benefit ratios. Key points of consensus were that deprescribing: (1) should not occur without first assessing medication adherence; (2) merits consideration if less than partial therapeutic response is apparent, or if treatment goals have been reached and relapse prevention is not a long-term objective; (3) involves psychological ramifications that warrant attention; (4) should be followed by close clinical monitoring; and (5) risk-benefit decisions should ideally involve active patient participation within a shared decision-making model. Conclusions and Relevance Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.
Associations between suppressive antibiotic therapy, treatment failure, and side effects among young, immunocompetent veterans with prosthetic joint infection who undergo debridement, antibiotics, and implant retention
Schweizer, Marin Leigh , Miell, Kelly , Merchant, James, Beck, Brice , Alexander, Bruce, Suh, Daniel , Suzuki, Hiroyuki, Tande, Aaron J. , Walhof, Julia , Haleem, Ambar , Suzuki, Hiroyuki , Alexander, Bruce , Suh, Daniel , Suzuki, Hiroyuki , Tande, Aaron , Dukes, Kimberly C , Walhof, Julia , Haleem, Ambar , Scolarici, Michael , Sekar, Poorani , Schweizer, Marin L. , Nair, Rajeshwari , Merchant, James, Puig‐Asensio, Mireia , Pugely, Andrew J.

Mayo Clinic

Antimicrobial Stewardship & Healthcare Epidemiology | February 23, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1017/ash.2025.10273 | PMID 41767648 Get It

Abstract Objective: Suppressive antibiotic therapy (SAT) is used to prevent recurrent prosthetic joint infections (PJI) among patients who undergo debridement, antibiotics, and implant retention (DAIR). We aimed to assess SAT outcomes among younger, immunocompetent patients. Design: Retrospective cohort study. Patients: Immunocompetent patients <65 years of age who received DAIR for PJI of the hip, knee, or shoulder. Setting: Veterans Affairs hospitals. Methods: SAT was divided into short-term (oral antibiotics given for <3 months after guideline concordant therapy) and long-term SAT (>3 months to 5 years of oral antibiotics). The primary outcome was treatment failure (TF) and mortality combined. SAT was a time-dependent covariate in Cox proportional hazards models. Results: Of the 938 patients, 15% received short-term SAT, 20% received long-term SAT, and 65% did not receive SAT. Short- and long-term SAT were significantly associated with decreased hazards of TF or mortality (short-term SAT adjusted hazard ratio (aHR) = 0.27; 95% confidence interval (CI): 0.11, 0.67; Long-term SAT aHR = 0.52; 95% CI: 0.30, 0.89). Short-term SAT was significantly associated with C. difficile infection (aHR: 3.47; 95% CI: 1.38, 8.74). Short-term SAT (aHR: 7.83; 95% CI: 4.80, 12.77) and long-term SAT (aHR: 1.68; 95% CI: 1.19, 2.38) were significantly associated with antibiotic-associated diarrhea. Long-term SAT was not significantly associated with TF alone (aHR = 0.61; 95% CI: 0.32, 1.16). Conclusions: SAT was significantly associated with decreased death or TF and increased side effects. Benefits and risks must be weighed before prescribing SAT to younger, immunocompetent patients.
Recurrent Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Left Atrial Appendage Occlusion
Ramadan, Adham, Doma, Mohamed , Félix, Iuri Ferreira , Ahmed, Mahmoud Samy, Mahmoud, Ahmed K., Ismayl, Mahmoud, Karara, Yehia , Villablanca, Pedro A., Saw, J, DeSimone, Christopher V., Doma, Mohamed , Ferreira Felix, Iuri , Mahmoud, Ahmed K , DeSimone, Christopher V , Ramadan, Adham, Kamel, Ibrahim, Ismayl, Mahmoud , Villablanca, Pedro, Saw, Jacqueline , DeSimone, Christopher V. , Goldsweig, Andrew M.

Mayo Clinic

Pacing and Clinical Electrophysiology | February 21, 2026 | Volume: 49 | Issue: 7 | Pages: 898-910

10.1111/pace.70177 | PMID 41721735 Get It

ABSTRACT Background Concomitant atrial fibrillation (AF) and gastrointestinal (GI) bleeding present a clinical challenge due to recurrent bleeding risk associated with anticoagulation for AF‐associated stroke prevention. Left atrial appendage occlusion (LAAO) offers an alternative stroke prevention strategy, but its impact on recurrent GI bleeding remains unknown. Methods This retrospective, multicenter cohort study used the TriNetX database to identify adults with AF on oral anticoagulation and a history of GI bleeding. Patients were stratified by treatment with or without LAAO. 1:1 propensity score matching (PSM) was employed. The primary outcome was recurrent GI bleeding. Cox regression analysis was used to generate hazard ratios (HRs) with 95% confidence intervals (CIs). Odds ratios (ORs) were used to evaluate effect sizes between groups. Kaplan–Meier curves were used for time‐to‐event analyses. Results After PSM, 9259 patients were compared in each group. Odds of recurrent GI bleeding were consistently lower in patients undergoing LAAO than without LAAO across all follow‐up intervals: at 3 months (OR 0.84; 95% CI 0.78–0.91), 6 months, 1 year, 3 years, and 5 years (OR 0.87; 95% CI 0.82–0.92). Kaplan–Meier analysis demonstrated significantly lower risk of recurrent GI bleeding with LAAO (HR 0.80; 95% CI 0.76–0.84; p < 0.01). Conclusion In patients with AF and prior GI bleeding, LAAO was associated with a significantly lower risk of recurrent GI bleeding at short‐term and long‐term time intervals.
A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling
Zanetti, Giorgia , Chen, A. C., Fathi, Farshid, Suek, Nathan , Teteloshvili, Nato , Li, Hao Wei , Ding, Xiaolan , Traum, Daniel , Kaestner, Klaus, Hoang, Ryan E., Bremer, Edwin , Parent, Audrey V. , Sykes, Megan, Maharlooei, Mohsen Khosravi, Khosravi-Maharlooei, Mohsen , Legut, Mateusz , Fathi, Farshid , Kaestner, Klaus H. , Sewell, Andrew Kelvin , Creusot, Rémi J.

Mayo Clinic

No container title available | February 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.19.706929 | PMID 41756994 Get It

Abstract Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, which impairs efficacy and poses risks of off-target autoreactivity. Here we present a CRISPR-based platform that completely and selectively eliminates both endogenous TCR-α and -β chains without affecting introduced transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, markedly enhancing the expression, pairing fidelity, and functional potency of transgenic receptors. Using a clinically relevant HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and significantly enhances tumor clearance in vivo in human immune system (HIS) mice, while preventing graft-versus-host disease (GVHD). Targeted locus amplification revealed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, confirming genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that removal of endogenous receptors increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of stem cell–derived islet grafts (SC-islets) in vivo . This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a strong preclinical rationale for dual endogenous TCR removal as a route to improved specificity, safety, and therapeutic efficacy in TCR-based cell therapies.
Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study
Wirbel, Jakob , Saber, Wael, Andermann, Tessa M, Fei, Teng , Brooks, Erin F. , Doyle, Boryana , Pincus, Nathan B. , Bar, Merav , Bolaños-Meade, Javier, Chhabra, Saurabh, Choi, Sung Won , Clark, William, Elmariah, Hany, Jones, Richard J. , Jp, Levine, Logan, Brent R, Malki, Monzr M Al, Rashidi, Armin, Rezvani, Andrew R. , Riches, Marcie L., Runaas, Lyndsey, Sandhu, Karamjeet , Spahn, Ashley, Horowitz, MM, Hamadani, Mehdi, Kean, Leslie S. , Perales, Miguel-Angel, Bhatt, Ami S. , Choi, Sung Won , Elmariah, Hany , Andermann, Tessa M. , Saber, Wael , Martens, Michael J , Peled, Jonathan U , Andermann, Tessa M , Fei, Teng , Brooks, Erin F , Doyle, Boryana , Pincus, Nathan B , Jenq, Robert R , Bar, Merav , Bratrude, Brandi , Chhabra, Saurabh , Elmariah, Hany , Gooptu, Mahasweta , Holtan, Shernan , Al Malki, Monzr M , Murthy, Hemant S , Rashidi, Armin , Rezvani, Andrew R , Sung, Anthony D , van den Brink, Marcel R M , Kean, Leslie S , Perales, Miguel-Angel , Bhatt, Ami S , Choi, Sung Won , Saber, Wael , Martens, Michael J. , Peled, Jonathan U. , Jenq, Robert R. , Bolaños‐Meade, Javier , Clark, William, Das, Suman R. , Holtan, Shernan G. , Logan, Brent R. , Malki, Monzr M. Al , Murthy, Hemant S. , Rashidi, Armin , Riches, Marcie , Sung, Anthony D. , Hamadani, Mehdi , Perales, Miguel‐Angel

Mayo Clinic

No container title available | February 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.19.706769 | PMID 41756883 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for many hematological malignancies, but graft-versus-host disease (GVHD) is a common complication. Low gut microbiome diversity is associated with higher GVHD risk and shorter survival in multiple studies. Recently, the BMT CTN 1703 clinical trial demonstrated superiority of a GVHD-prophylaxis regimen including post-transplant cyclophosphamide (PTCy) compared to the standard prophylaxis (tacrolimus and methotrexate, Tac/MTX) in terms of GVHD-free, relapse-free survival at one year among reduced intensity conditioning allo-HCT recipients. However, the effect of PTCy on the gut microbiome and its association with clinical outcome have not been described. Here, we report on a companion randomized clinical controlled trial (BMT CTN 1801), which collected 2575 longitudinal stool samples from 304 study participants. Samples were obtained up to weekly up to day 84 post allo-HCT and at less frequent intervals thereafter, up to 2 years. Microbiome diversity and absolute microbial load were lower in the PTCy group compared to the Tac/MTX group on days 14–28 post-HCT. However, diversity at the timepoint closest to neutrophil engraftment was not significantly associated with non-relapse mortality after one year or other clinical outcomes, contrary to expectations from previous studies. Microbial domination events, when a single species exceeds 30% relative abundance, were comparable across treatment arms and reflected both pathogen blooms as well as less severe disruptions of the microbial community. Clostridium scindens and secondary bile acid metabolism pathways were less prevalent in the PTCy arm than in the Tac/MTX arm post-HCT, yet presence of secondary bile acid metabolism pathways was associated with a lower risk of chronic GVHD. Given that PTCy was associated with a greater disruption of the microbiome as measured by diversity, absolute microbial abundance, and bile acid metabolism capability, but better clinical outcomes overall, these data suggest that the importance of the microbiome in modulating the host immune systems after allo-HCT is specific to different types of GVHD prophylaxis.
Extrapancreatic Gastrointestinal Tract Grade 3 Well-Differentiated Neuroendocrine Tumors Behave Aggressively Compared With Lower-Grade Tumors Despite Similar Morphology
Vyas, Monika, Bellizzi, Andrew M., McHugh, Kelsey , Allende, Daniela, Shi, Chanjuan, Ma, Changqing , Shroff, Stuti G. , Cox, Brian , Padmanabha, Nandan , Gonzalez, Raul S , McHugh, Kelsey E , Bellizzi, Andrew M. , Singhi, Aatur Dilip , González, Raul S.

Mayo Clinic

American Journal of Surgical Pathology | February 20, 2026 | Volume: 50 | Issue: 5 | Pages: 524-534

10.1097/pas.0000000000002514 | PMID 41717808 Get It

The WHO 2019 classification of digestive tract tumors introduced a high-grade (G3) category for well-differentiated neuroendocrine tumors (NETs). These neoplasms appear to have a better prognosis than poorly differentiated neuroendocrine carcinomas (NECs) and may not respond to platinum-based chemotherapy, which is the treatment of choice for NECs, justifying the creation of this new category. Most existing data on G3 NETs are derived from pancreatic neuroendocrine neoplasms, as the majority of G3 neuroendocrine neoplasms (NENs) arise there. G3 NETs are rare at extrapancreatic sites, and their prognosis and behavior are not well studied. We collected and analyzed a multi-institutional cohort of 24 extrapancreatic primary gastrointestinal G3 NETs based on mitotic rate and/or Ki67 index (5 gastric, 13 small bowel, 6 colorectal/anal). Mean Ki67 index was 29.3% (range: 10.5% to 50.2%). Cases generally showed typical well-differentiated NET morphology. Nodal metastases were present in 17/17 (100%) patients; 13/24 (45%) had distant metastases at initial presentation, and 7 patients developed them on follow-up. With a median of 29 months of follow-up, only 2 patients (8%) were alive without disease. Outcomes of G3 NETs were compared with a separate cohort of 125 extrapancreatic G1/G2 gastrointestinal NETs. G3 tumors presented at a higher pT-category stage ( P <0.001) and overall stage ( P =0.002), and patients with G3 disease were more likely to die than those with G1/G2 disease ( P <0.001). Our data show that, like pancreatic G3 NETs, rare extrapancreatic gastrointestinal G3 NETs exhibit aggressive behavior compared with their G1/G2 counterparts (although small bowel NETs tend to recur irrespective of grade). In most cases, the G3 designation is driven by Ki67 index, though exceptions exist, emphasizing the need for reviewing mitotic count in every case.
Sickle cell related cardiomyopathy and cardiovascular autonomic dysfunction
Hartnett, Jack, Connolly, N, Quinn, Sandra, Murphy, Ross, Tuohy, Emma, Curtain, James P. , Hartnett, Jack , Connolly, Niall, Quinn, Sandra , Murphy, Ross T. , Mogensen, Jens , Kenny, Rose Anne , Maree, Andrew

Mayo Clinic

Frontiers in Cardiovascular Medicine | February 19, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1756623 | PMID 41798613 Get It

Sickle cell disease (SCD) is the most common genetic haemoglobinopathy worldwide. Due to advancements in care, SCD patients are living longer. Consequently, there is increased interest in long term sequalae of chronic micro-vascular sickling and resultant end organ damage. Sickle cell cardiomyopathy is an emerging clinical entity characterised by a unique combination of ventricular dilatation, ventricular hypertrophy, diastolic dysfunction and pulmonary hypertension. Additionally, SCD patients have impaired autonomic function which is thought to pre-dispose to vaso-occlusive crises through sympathetic activation and parasympathetic withdrawal during times of physiologic stress. Furthermore, sudden death is a major cause of mortality among patients with SCD, however the mechanism has not been elucidated. This review summarizes the sickle cell cardiomyopathy literature, its relationship with autonomic dysfunction and its association with sudden death.
Perception of Anatomical Nasal Variants Among Lay Observers: Clinical Insights from an Eye-Tracking Study
Awadallah, Andrew S. , Khalil, Yousuf H. , Shurtz, Anne K., Schwartz, Jenna , Staricha, Kelly L., Hamilton, Grant S., Awadallah, Andrew , Shurtz, Anne K., Staricha, Kelly L. , Dey, Jacob K. , Hamilton, Grant S.

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/26893614261422622 | PMID 41711167 Get It

Background: Facial appearance influences social perception, with laypersons focusing on the central facial triangle; nasal differences may alter gaze patterns, but few studies have quantified this using eye-tracking. Objective: To evaluate how layperson gaze patterns shift in response to different nasal variations as measured by eye-tracking. Methods: In this prospective cohort study, facial images with 30 nasal differences were created using Photoshop to represent a range of phenotypes, such as dorsal hump, crooked nose, and pinched tip, alongside controls. Gaze data were captured via eye-tracking, and linear mixed-effects modeling assessed differences in time spent viewing defined areas of interest, adjusting for participant and image variables. Results: A total of 119 participants (53.8% female) were enrolled. The median age was 40 years, and 82% identified as Caucasian. Among the 30 nasal alterations, only the saddle nose resulted in significantly increased gaze time compared to controls (mean increase: 0.89 s; p < 0.001). Participant age, sex, and gender of the face in the image did not significantly influence gaze behavior. Conclusion: In this study, only the saddle nose attracted greater visual attention from lay observers compared with other nasal variants.